C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

As described in a recent JAMA Viewpoint, the proposed national HCV elimination program intends to engage underserved populations in need of HCV treatment by working closely with grassroots ...

Atea Pharmaceuticals, Inc. ( (AVIR)) has released its Q3 earnings. Here is a breakdown of the information Atea Pharmaceuticals, Inc. presented to its investors. Atea Pharmaceuticals, Inc. is a ...

Please provide your email address to receive an email when new articles are posted on . Among 133,732 veterans with HCV, 80.1% initiated treatment and 91.6% achieved SVR. Younger veterans were less ...

Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...

Please provide your email address to receive an email when new articles are posted on . Georgia’s hepatitis C virus elimination program made significant progress in helping diagnose patients and begin ...

Dr. James W. Galbraith joined the University of Alabama at Birmingham (UAB) Emergency Medicine faculty in 2008. In 2011, Dr. Galbraith led the implementation of emergency department (ED) non-targeted, ...

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...

Regulus Therapeutics Inc. is halting development of its lead microRNA candidate, RG-101, an N-acetylgalactosamine (GalNAc)-conjugated asset targeting miR-122 in chronic hepatitis C virus (HCV), rather ...

(HealthDay News) — A hepatitis C virus (HCV) screening program diagnosed chronic HCV infection in 4.2% of baby boomers tested, according to a study published in the August issue of the Journal of ...